sabato, 3 giugno 2023

Notizie AIOM – anno XVI n. 693

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, cofirmati da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

ASCO Supports Expanded Adjuvant Therapy for Early Breast Cancer

October 1, 2018 - Patients with early-stage breast cancer facing a high risk of recurrence would benefit from the expanded use of adjuvant therapy, according to updated guidelines from the American Society of Clinical Oncoogy (ASCO). The recommendations cover clinical scenarios ...
Leggi tutto

Boosting the development of medicines for children

October 2, 2018 - The European Medicines Agency (EMA) and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have published today a PDF iconjoint action plan to support the development of medicines for children in Europe. The action ...
Leggi tutto

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1-4 October 2018

October 5, 2018 - At its monthly meeting, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) concluded a referral and confirmed its advice in the context of a safety signal evaluation. More information on all safety referrals currently ...
Leggi tutto

Spending on Antineoplastic Agents in the United States, 2011 to 2016

Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative ...
Leggi tutto

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma

Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited. To examine the potential benefits of aspirin use for primary HCC prevention at a range of doses and durations of use within 2 prospective, nationwide ...
Leggi tutto

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

About one-third of patients with renal cell carcinoma (RCC) have detectable metastases at diagnosis. Among them, bone is the second most frequent metastatic site. Treatment of metastatic RCC mostly relies on anti-angiogenic (AA) therapies and, more recently, immunotherapy. ...
Leggi tutto

1 ottobre 2018 – Aggiornamento: Procedura operativa per le attività dei Responsabili Locali di Farmacovigilanza (RLFV)

1 ottobre 2018 – Pubblicazione schede di monitoraggio Registro Nivolumab (Bristol-Myers Squibb) (cHL)

1 ottobre 2018 – Chiusura Registro di Monitoraggio Rituximab (Roche) secondo Legge 648/96